Monopar Therapeutics (MNPR) EBIAT (2017 - 2019)
Historic EBIAT for Monopar Therapeutics (MNPR) over the last 3 years, with Q4 2019 value amounting to -$1.2 million.
- Monopar Therapeutics' EBIAT fell 3553.19% to -$1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.2 million, marking a year-over-year decrease of 3864.88%. This contributed to the annual value of -$4.2 million for FY2019, which is 3088.49% down from last year.
- Monopar Therapeutics' EBIAT amounted to -$1.2 million in Q4 2019, which was down 3553.19% from -$736080.0 recorded in Q3 2019.
- Monopar Therapeutics' EBIAT's 5-year high stood at -$372915.0 during Q1 2017, with a 5-year trough of -$14.9 million in Q3 2017.
- For the 3-year period, Monopar Therapeutics' EBIAT averaged around -$2.0 million, with its median value being -$806213.5 (2018).
- The largest annual percentage gain for Monopar Therapeutics' EBIAT in the last 5 years was 9569.68% (2018), contrasted with its biggest fall of 13499.91% (2018).
- Monopar Therapeutics' EBIAT (Quarter) stood at -$713583.0 in 2017, then fell by 24.79% to -$890461.0 in 2018, then plummeted by 35.53% to -$1.2 million in 2019.
- Its EBIAT was -$1.2 million in Q4 2019, compared to -$736080.0 in Q3 2019 and -$905700.0 in Q2 2019.